Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Potential of immunotherapy to convert a complete cytogenetic remission in chronic myelogenous leukemia to a molecular complete remission: randomized phase II study of proteinase 3 PR1 peptide mixed with montanide ISA-51 VG adjuvant and administered with GM-CSF [granulocyte macrophage colony-stimulating factors] and peginterferon alfa-2b [PEG-INTRON, Schering Corporation].

X
Trial Profile

Potential of immunotherapy to convert a complete cytogenetic remission in chronic myelogenous leukemia to a molecular complete remission: randomized phase II study of proteinase 3 PR1 peptide mixed with montanide ISA-51 VG adjuvant and administered with GM-CSF [granulocyte macrophage colony-stimulating factors] and peginterferon alfa-2b [PEG-INTRON, Schering Corporation].

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PR1 peptide vaccine (Primary) ; Imatinib; Peginterferon alfa-2b; Sargramostim
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
    • 25 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 23 Mar 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top